Authors

• Philippe Généreux (ORCID: https://orcid.org/0000-0002-5507-3712)
• Philippe Pîbarot (ORCID: https://orcid.org/0000-0002-3607-279X)
• Marie-Annick A Clavel (ORCID: https://orcid.org/0000-0002-8924-740X)
• Xander Jacquemyn (ORCID: https://orcid.org/0000-0001-8421-0686)
• Omar Abdelfattah (ORCID: https://orcid.org/0000-0001-8025-9212)
• Samir Kapadia (ORCID: https://orcid.org/0000-0002-0026-3391)
• Martin B. Leon (ORCID: https://orcid.org/0000-0002-2002-7492)
• Nicholas Van Meighem

Institutions

• Cleveland Clinic (US)
• NewYork–Presbyterian Hospital (US)
• Columbia University Irving Medical Center (US)
• New York Hospital Queens (US)
• Erasmus MC (NL)
• Morristown Medical Center (US)
• Cardiovascular Research Foundation (US)
• Université Laval (CA)
• The University of Texas Medical Branch at Galveston (US)
• KU Leuven (BE)

Publication Details

Journal

JACC Advances

Published

2024-08-16

DOI

https://doi.org/10.1016/j.jacadv.2024.101190

Citations

5

Primary Topic

Cardiac Valve Diseases and Treatments

Type

article

Field-Weighted Citation Impact

2.01

Funders

• Edwards Lifesciences
• iRhythm Technologies
• Cleveland Clinic
• Université Laval
• Boston Scientific Corporation
• Abiomed
• KU Leuven
• Abbott Vascular
• Erasmus Universitair Medisch Centrum Rotterdam